Business Context and Reporting Period
This Form 8-K Current Report was filed by Corbus Pharmaceuticals Holdings, Inc. on March 30, 2020, with the earliest event reported dated April 1, 2020. The filing discloses the approval of amended and restated employment agreements for three executive officers, effective April 11, 2020.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation arrangements.
Material Changes
The primary material change is the execution of new employment contracts for the following executives, effective April 11, 2020:
- Yuval Cohen, Ph.D. (CEO): Two-year term with an annual base salary of $559,000 and a target annual bonus of up to 60% of base salary.
- Barbara White, M.D. (CMO): Two-year term with an annual base salary of $439,000 and a target annual bonus of up to 40% of base salary.
- Sean Moran (CFO): Two-year term with an annual base salary of $400,000 and a target annual bonus of up to 40% of base salary.
Outlook, Risks, and Unusual Items
The agreements include specific severance provisions triggered by termination without cause or resignation for good reason:
- Standard Termination: All three executives are eligible for 12 months of base salary and 12 months of COBRA coverage reimbursement.
- Change in Control Period: Severance increases to 24 months of base salary for the CEO and 18 months for the CMO and CFO. Additionally, the CEO receives accelerated vesting of equity and a bonus at 2x target, while the CMO and CFO receive accelerated vesting and a bonus at 1x target.
- Golden Parachute Provisions: Payments are subject to reduction under Internal Revenue Code Section 4999 to avoid excise taxes.
Investor Verification Checklist
- Verify the exact effective date of the new agreements (April 11, 2020) against the company's internal records.
- Review the attached Exhibits 10.1, 10.2, and 10.3 for the full legal text of the employment contracts.
- Confirm the current status of the company's equity incentive plans referenced for future awards.
- Assess the potential cash impact of the increased severance obligations in the event of a Change in Control.